ANI Pharmaceuticals
ANIP
106 hedge funds and large institutions have $263M invested in ANI Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 30 increasing their positions, 46 reducing their positions, and 21 closing their positions.
23% more capital invested
Capital invested by funds: $214M → $263M (+$49.1M)
4% more call options, than puts
Call options by funds: $415K | Put options by funds: $400K
0.63% less ownership
Funds ownership: 59.68% → 59.05% (-0.63%)
9% less funds holding
Funds holding: 117 → 106 (-11)
35% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 46
48% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 21
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$2.51M |
| 2 |
BlackRock
New York
|
+$1.94M |
| 3 |
FWSM
First Wilshire Securities Management
Pasadena,
California
|
+$1.85M |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
+$1.81M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.75M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Man Group
London,
United Kingdom
|
-$2.06M |
| 2 |
Russell Investments Group
London,
United Kingdom
|
-$1.85M |
| 3 |
Morgan Stanley
New York
|
-$1.59M |
| 4 |
Renaissance Technologies
New York
|
-$1.3M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
-$1.08M |
ANIP Hedge Fund Activity: Q1 2021 in Review
106 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2021, worth a combined $263M — up 23% from $214M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of ANIP and 11 opened new positions — a net loss of 10 holders — while 46 trimmed existing stakes and 30 added.
The largest buyer was State Street, adding an estimated $2.51M. The largest seller was Man Group, exiting entirely with an estimated $2.06M sold.
- 106 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2021, down from 117 in Q4 2020.
- Funds reported $263M of ANI Pharmaceuticals stock for Q1 2021, up 23% quarter-over-quarter.
- 11 funds opened new ANI Pharmaceuticals positions in Q1 2021 and 21 closed out, a net change of -10 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2021 was State Street, an estimated $2.51M added.
- The largest ANI Pharmaceuticals seller in Q1 2021 was Man Group, an estimated $2.06M sold.
Based on aggregated 13F filings for Q1 2021.